SCHEMBL664937

SCHEMBL664937

CCCCCCN1CCCCCC1=O

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.46
GAA P10253 1/20 0.46
FAAH O00519 1/20 0.45
MGLL Q99685 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
RAB9A P51151 1/20 0.43
PIK3CD O00329 1/20 0.42
ADRA1B P35368 1/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
GBA1 P04062 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10816721 1.00 ALOX5 (0.46) ALOX5GAAFAAHMGLLL3MBTL1
Laurocapram SCHEMBL23347 1.00 ALOX5 (0.46) ALOX5GAAFAAHMGLLL3MBTL1
SCHEMBL11851404 1.00 ALOX5 (0.46) ALOX5GAAFAAHMGLLL3MBTL1
SCHEMBL11847945 1.00 ALOX5 (0.46) ALOX5GAAFAAHMGLLL3MBTL1
SCHEMBL11849011 1.00 ALOX5 (0.46) ALOX5GAAFAAHMGLLL3MBTL1
SCHEMBL11855053 1.00 ALOX5 (0.46) ALOX5GAAFAAHMGLLL3MBTL1
SCHEMBL10481688 1.00 ALOX5 (0.46) ALOX5GAAFAAHMGLLL3MBTL1
SCHEMBL8967917 1.00 ALOX5 (0.46) ALOX5GAAFAAHMGLLL3MBTL1
SCHEMBL5858660 1.00 ALOX5 (0.46) ALOX5GAAFAAHMGLLL3MBTL1
SCHEMBL10427195 1.00 ALOX5 (0.46) ALOX5GAAFAAHMGLLL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030134420-A1 Methods and compositions for gene delivery IMMUNE RESPONSE CORPORATION, THE 2003-07-17 US claimed
WO-2001060415-A1 METHODS AND COMPOSITIONS FOR GENE DELIVERY THE IMMUNE RESPONSE CORPORATION (US) 2001-08-23 WO claimed
EP-0167907-B1 ACTIVATED ANIONIC POLYMERIZATION OF LACTAMS BAYER AG (DE) 1992-03-11 EP claimed
US-20250195409-A1 METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES Ananda Scientific, Inc. (US) 2025-06-19 US disclosed
EP-3543310-B2 COMPOSITIONS COMPRISING HFC-1234YF AND HFC-32 CHEMOURS CO FC LLC (US) 2024-07-03 EP disclosed
EP-3299435-B1 METHOD OF PREPARING A COMPOSITION COMPRISING HFC-1234YF CHEMOURS CO FC LLC (US) 2024-06-26 EP disclosed
EP-3309233-B2 COMPOSITIONS COMPRISING HFC-1234YF AND HFC-152A CHEMOURS CO FC LLC (US) 2024-02-21 EP disclosed
EP-2749623-B2 Method for replacing a high GWP refrigerant in a refrigeration, air-conditioning, or heat pump apparatus CHEMOURS CO FC LLC (US) 2024-02-21 EP disclosed
CN-113549426-B Compositions comprising fluoroolefins 科慕埃弗西有限公司 2023-11-14 CN disclosed
US-20230265330-A1 COMPOSITIONS COMPRISING A FLUOROOLEFIN THE CHEMOURS COMPANY FC, LLC (US) 2023-08-24 US disclosed
US-11674067-B2 Compositions comprising a fluoroolefin THE CHEMOURS COMPANY FC, LLC (US) 2023-06-13 US disclosed
EP-0077078-B1 METHOD FOR IMPROVED PLANT PEST CONTROL Whitby Research Incorporated (US) 1986-10-15 EP disclosed
EP-0167907-A2 Activated anionic polymerization of lactams BAYER AG (DE) 1986-01-15 EP disclosed
US-4525199-A Method of improved pest control NELSON RESEARCH & DEVELOPMENT CO. (US) 1985-06-25 US disclosed
US-4444762-A Vehicle composition containing 1-substituted azacyclopentan-2-ones NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1984-04-24 US disclosed
US-4424210-A Vehicle composition containing 1-substituted azacycloalkan-2-ones NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1984-01-03 US disclosed
US-4423040-A Vehicle composition containing 1-substituted azacyclohexan-2-ones NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1983-12-27 US disclosed
US-4415563-A TOPICAL APPLICATION OF MEDICINE; COSMETICS NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1983-11-15 US disclosed
EP-0077078-A1 Method for improved plant pest control Whitby Research Incorporated (US) 1983-04-20 EP disclosed
US-4316893-A USED FOR TOPICAL APPLICATION WITH A PHYSIOLOGICALLY ACTIVE AGENT NELSON RESEARCH & DEVELOPMENT CO. (US) 1982-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195409-A1 METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES CNR2, CNR1, FAAH ALOX5 34/4885GAA 2993/4885FAAH 3/4885
US-20030134420-A1 Methods and compositions for gene delivery POLRMT, NUP205, POLM ALOX5 4662/4885GAA 1759/4885FAAH 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.